The ABPI today announced the last disclosure of aggregate payments from the pharmaceutical industry to healthcare professionals before the new, individual payments disclosure database becomes operational in 2016.
New figures show that payments from the pharmaceutical industry to doctors, nurses and other healthcare professionals during 2014 are estimated to be around £41 million1 across 50 ABPI member companies. This is slightly higher than payments made in 2013 (£38.5 million in respect of 34 companies) and 2012 (£40 million in respect of 35 companies). The 2014 figure relates to 28,556 relationships with healthcare professionals.
This is the last year that aggregate payments will be disclosed in this way as, from 30 June 2016, industry will be reporting
payments made to individual, named, healthcare professionals2, starting with payments made during 2015, on a searchable database managed by the ABPI. This new platform will include payments for categories of activity currently not disclosed in aggregate figures3 and signals industry’s commitment to increased transparency in its relationships with healthcare professionals and healthcare organisations.
“Our relationships with healthcare professionals are paramount to developing life-saving and life-enhancing medicines,” said Dr Virginia Acha, ABPI’s Executive Director Research, Medical and Innovation. “By working with doctors, nurses, pharmacists and other health professionals we are able to combine knowledge of innovative new treatments with clinical best practice to ensure the best possible outcomes for patients.
“We are committed to being transparent about these relationships and we have become increasingly more open about the payments being made for these collaborations. This year marks the end of aggregate reporting of payments in this way and heralds the start of an era of even more openness when payments to individual healthcare professionals will be disclosed for a wider range of activities.
“We are currently engaging with representative bodies of healthcare professionals to explain industry’s commitment to increased transparency and we hope as many healthcare professional as possible will agree to their data being published on the new database in support of this increased transparency.”
More information about the new database and how it will affect individual healthcare professionals and healthcare organisations can be found on
our disclosure pages.
Fees for consultancy services – this includes but is not limited to activities such as speaking at and chairing meetings, participating in advisory board meetings, involvement in medical/scientific studies, clinical trials or training services and undertaking media activity, including filming and participation in market research activity (under relevant contractual agreement).
Financial sponsorship for attendance at independent (third party organised) medical education meetings – Covering registration fees, international travel, accommodation and reasonable refreshments/subsistence etc.
ABPI member companies, and non-members who voluntarily comply with the Code, are required to disclose their company’s own figures on their website three months after the end of their financial year. Companies will also publish the number of healthcare professionals they have worked with in both of these categories.
These figures cover payments in relation to 28,556 relationships between pharmaceutical companies and healthcare professionals. Relationships do not equate to individuals as it is possible that some healthcare professionals work with more than one company and therefore we cannot simply add the number of healthcare professionals disclosed by companies for an aggregate figure.
The current aggregate disclosure requirements cover consultancy fees, associated accommodation, and overseas travel; and sponsorship to attend events organised by third parties.
Where recipients of transfers of value cannot be identified for legal reasons, the amount attributable to such transfers will be disclosed on an anonymised, aggregate basis.
Payments for healthcare professionals’ participation in research and development activities with companies, including clinical trials, will be disclosed in aggregate on the new database.
The database will also include transfers of value to healthcare organisations including fees for services, contributions towards events and joint working in addition to existing requirements to disclose grants and donations. The aggregate spend on certain research and development will also be disclosed.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: